

Hemoglobin A1c Testing Markets



Phone: +44 20 8123 2220
Fax: +44 207 900 3970
office@marketpublishers.com
<http://marketpublishers.com>

Hemoglobin A1c Testing Markets

Date:	July 1, 2014
Pages:	131
Price:	US\$ 3,400.00
ID:	H80F53DC117EN

Hemoglobin A1c (HbA1c) testing is the most recent major technology to have entered the diabetes testing market. As the global prevalence of diabetes mellitus continues to increase rapidly, with more than 366 million diabetics worldwide, hemoglobin A1c testing is now an essential assay in the diabetes testing repertoire. Its clinical utility and improvements in its accuracy and implementation of standardized protocols have translated into continued market growth. This TriMark Publications report describes the specific market segment that encompasses hemoglobin A1c testing for diagnosing and monitoring diabetes. The study reviews all of the generally accepted clinical analytical methods that are currently in use today for measuring HbA1c levels. Moreover, it examines clinical measurement devices and reagents as utilized in hospitals, clinics, doctor's offices and at-home care locations. The report also analyzes almost all of the companies known to be marketing, manufacturing or developing hemoglobin A1c testing. Detailed tables and charts with sales forecasts and marketshare data are also included.

Table of Content

1. OVERVIEW

- 1.1 Statement of Report
- 1.2 About This Report
- 1.3 Scope of the Report
- 1.4 Methodology
- 1.5 Executive Summary

2. DIABETES

- 2.1 Demographics of Diabetes
 - 2.1.1 Worldwide Diabetes Incidence
 - 2.1.2 Diabetes in the U.S.
- 2.2 Understanding the Metabolic Conditions Underlying and Associated with Diabetes
 - 2.2.1 Pre-Diabetes Syndrome
 - 2.2.2 Metabolic Syndrome
 - 2.2.3 Progression of Diabetes
 - 2.2.4 Diabetes and Inflammation
 - 2.2.5 Risk Factors and Diabetes
 - 2.2.5.1 Obesity
 - 2.2.5.2 Stress-Induced Hyperglycemia
 - 2.2.6 Complications and Co-Morbidities in Diabetes
 - 2.2.6.1 Preventing Complications and Co-Morbidities in Diabetes
 - 2.2.6.2 Cardiovascular Disease Facts
- 2.3 Economics of Diabetes
 - 2.3.1 Worldwide Costs of Diabetes
 - 2.3.2 Costs of Diabetes in the U.S.

3. MARKET ANALYSIS: SIZE, GROWTH, SHARE AND COMPETITORS

- 3.1 Worldwide HbA1c Testing Market
 - 3.1.1 U.S. HbA1c Testing Market
- 3.2 HbA1c Self-Testing Market
- 3.3 Competitive Situation
 - 3.3.1 Analyses of the Key Players, Current Market Conditions, and Product Mix
 - 3.3.2 Competitive Strategies and Strategic Recommendations
 - 3.3.3 Future Competing Technologies—Glycated Albumin
- 3.4 Market Drivers and Restraints
 - 3.4.1 Market Drivers
 - 3.4.2 Market Restraints
- 3.5 Market and Product Trends
 - 3.5.1 Increase in POC HbA1c Testing
 - 3.5.2 Move Towards Screening for Diabetes Using HbA1c Assays
- 3.6 Adjacent Markets

4. OVERVIEW OF HBA1C TESTING

- 4.1 Technology Platforms Used to Measure HbA1c
 - 4.1.1 High-Performance Liquid Chromatography (HPLC)
 - 4.1.2 Immunoassays
 - 4.1.3 Boronate Affinity Chromatography
 - 4.1.4 Enzymatic Assay
 - 4.1.5 Micro-Optical Detection Methods
- 4.2 Development of HbA1c Testing: A Historical Evaluation
 - 4.2.1 The Diabetes Control and Complications Trial (DCCT)
- 4.3 Standardization of HbA1c Testing and Certification Criteria
 - 4.3.1 National Glycohemoglobin Standardization Program (NGSP)
 - 4.3.2 International Federation of Clinical Chemistry (IFCC)
 - 4.3.3 New NGSP Certification Criteria Beginning in January 2014
 - 4.3.4 ADAG (A1c Derived Average Glucose)
 - 4.3.5 2010 Consensus Statement on the Worldwide Standardization of HbA1c
 - 4.3.6 College of American Pathologists (CAP) Proficiency Program
 - 4.3.7 Certifications and Selecting HbA1c Assays
- 4.4 Advantages and Disadvantages of HbA1c Assessment
- 4.5 HbA1c Testing Recommendations
 - 4.5.1 Frequency of HbA1c Testing
 - 4.5.2 Diagnostic HbA1c Testing
 - 4.5.3 Screening for Pre-Diabetes
 - 4.5.4 HbA1c Testing for Diabetes Management and Glycemic Goals
- 4.6 Accuracy and Precision in HbA1c Testing
 - 4.6.1 Biological Variation
 - 4.6.2 Pre-Analytical Variation
 - 4.6.3 Analytical Variation
- 4.7 Potential Interfering Variables Affecting HbA1c Testing
- 4.8 Potential Areas of Improvement in HbA1c Testing Performance
- 4.9 Optimizing of Point of Care (POC) HbA1c Testing
- 4.10 Key Issues for HbA1c Testing
- 4.11 HbA1c Testing and Blood Glucose Testing: Complementary Tools

5. HBA1C TESTING DEVICES ON THE MARKET

- 5.1 HbA1c Self-Testing Devices
 - 5.1.1 A1CNow SELFCHECK
 - 5.1.2 DTI Laboratories, Inc.
 - 5.1.3 Heritage Labs International (part of Hooper Holmes)

- 5.1.4 Solana Health
- 5.2 Professional HbA1c Testing Devices
 - 5.2.1 Point of Care HbA1c Testing
 - 5.2.1.1 A. Menarini Diagnostics
 - 5.2.1.2 Alere
 - 5.2.1.3 Bio-Rad
 - 5.2.1.4 Convergent Technologies GmbH & Co.
 - 5.2.1.5 DiaSys Diagnostic Systems
 - 5.2.1.6 Diazyme Laboratories
 - 5.2.1.7 EKF Diagnostics
 - 5.2.1.8 HemoCue
 - 5.2.1.9 Infopia
 - 5.2.1.10 Roche
 - 5.2.1.11 Siemens Healthcare Diagnostics
 - 5.2.2 HbA1c Laboratory Testing
 - 5.2.2.1 Abbott
 - 5.2.2.2 Arkray
 - 5.2.2.3 Beckman Coulter
 - 5.2.2.4 Bio-Rad
 - 5.2.2.5 DiaSys Diagnostic Systems
 - 5.2.2.6 Diazyme Laboratories
 - 5.2.2.7 EKF Diagnostics
 - 5.2.2.8 Kyowa Medex, Co., Ltd.
 - 5.2.2.9 Ortho Clinical Diagnostics (part of Johnson & Johnson)
 - 5.2.2.10 Pointe Scientific, Inc.
 - 5.2.2.11 Randox Laboratories
 - 5.2.2.12 Roche
 - 5.2.2.13 Sebia
 - 5.2.2.14 Siemens Healthcare Diagnostics
 - 5.2.2.15 Tosoh
 - 5.2.2.16 Trinity Biotech
- 5.3 New Product Innovations and Introductions
 - 5.3.1 Roche's Cobas Integra 800 Tina-quant HbA1cDx Assay is First FDA-Approved Test for Diagnosing Diabetes
 - 5.3.2 Abbott Announces FDA Clearance for a its ARCHITECT Clinical Chemistry Hemoglobin A1c Test for the Diagnosis and Monitoring of Diabetes
 - 5.3.3 Sebia Announces a New HbA1c Test
 - 5.3.4 Sebia's CAPILLARYS 2 FLEX Piercing System
 - 5.3.5 Sebia's MINICAP Flex Piercing
 - 5.3.6 Shelf-Life of EKF Diagnostics' Quo-Lab HbA1c Test Extended
 - 5.3.7 Convergent Technologies Launches Convergys HbA1c at Medica 2013
 - 5.3.8 Beckman Coulter Receives FDA Clearance on Next Generation Hemoglobin A1c Test
 - 5.3.9 Trinity Biotech Launches the Premier Hb9210
 - 5.3.10 Trivitron to Enter HbA1c Market
 - 5.3.11 Siemens Healthcare Announced a New Version of the DCA Vantage Analyzer
 - 5.3.12 EKF Diagnostics to Launch the Quo-Lab HbA1c
 - 5.3.13 Tosoh Introduces the ST AIA-PACK HbA1c Assay
 - 5.3.14 Tosoh Introduces a Comprehensive HbA1c Product Line
- 5.4 Recent Industry Activity and Corporate Developments
 - 5.4.1 PTS, Inc. (now Chek Diagnostics) Acquires A1CNow from Bayer Diabetes Care
 - 5.4.2 Polymer Technology Systems, Inc. (PTS, Inc.) Changes Name to Chek Diagnostics
 - 5.4.3 EKF Diagnostics Quo-Test and Quo-Lab HbA1c POCT Analyzers Comparable to Laboratory HPLC
 - 5.4.4 Radiometer Medical ApS Acquires HemoCue AB
 - 5.4.5 Axis-Shield Acquired by Alere
 - 5.4.6 EKF Diagnostics Opens New Manufacturing Facility at its Quotient Diagnostics Base

- 5.4.7 EKF Diagnostics Acquires Quotient Diagnostics
- 5.4.8 EKF Diagnostics Acquires Stanbio Laboratories
- 5.4.9 Geonostics Acquires FlexSite's Diagnostics
- 5.4.10 Trinity Biotech Signs Distribution Agreements with Fisher and Menarini Diagnostics

6. BUSINESS TRENDS IN HbA1c TESTING

- 6.1 Drivers and Trends of Clinical HbA1c Testing
- 6.2 Healthcare Cost Controls
- 6.3 Affordable Care Act Excise Tax on Medical Devices
- 6.4 Changes in Patient Management
- 6.5 Regionalization of Laboratory Care
- 6.6 Satellite Facilities
- 6.7 Professional Point of Care Testing
 - 6.7.1 Key Issues in the POC Diagnostic Testing Sector
 - 6.7.2 Current Market Trends and Drivers
 - 6.7.3 POC HbA1c
 - 6.7.4 Effectiveness of POCT
 - 6.7.5 Key Customer Segments
- 6.8 Factors Affecting OTC Medical Product Distribution
- 6.9 Drivers and Restraints of OTC and Self-Testing HbA1c Markets

7. REGULATORY ENVIRONMENT AND INSURANCE REIMBURSEMENTS

- 7.1 U.S. Government Regulation of Medical Devices
- 7.2 E.U. Regulation of Medical Devices
- 7.3 FDA Labeling Requirements
- 7.4 Clinical Laboratory Improvement Act (CLIA)
- 7.5 HbA1c Testing Insurance Coverage and Reimbursement
- 7.6 Managed Care

8. COMPANY PROFILES

- 8.1 Abbott Laboratories
- 8.2 A. Menarini Diagnostics
- 8.3 Alere, Inc.
- 8.4 ARKRAY USA, Inc.
- 8.5 Axis-Shield Plc
- 8.6 Bayer Healthcare Diagnostics
- 8.7 Beckman Coulter, Inc
- 8.8 Bio-Rad Laboratories, Inc.
- 8.9 Chek Diagnostics
- 8.10 Convergent Technologies GmbH
- 8.11 DiaSys Diagnostics
- 8.12 Diazyme Laboratories (a Division of General Atomics)
- 8.13 EKF Diagnostics
- 8.14 HemoCue AB (now part of Radiometer Medical)
- 8.15 Infopia Co., Ltd.
- 8.16 Ortho Clinical Diagnostics (part of Johnson & Johnson)
- 8.17 Quotient Diagnostics
- 8.18 Randox Laboratories
- 8.19 Roche Diagnostics
- 8.20 Sebia
- 8.21 Siemens AG
- 8.22 Tosoh Bioscience, Inc.

8.23 Trinity Biotech Plc

INDEX OF FIGURES

- Figure 2.1: Worldwide Diabetes Cases, 2013 and 2035
 Figure 2.2: Worldwide Prevalence of Diabetes (%) in Adults (20-79 Years), 2013
 Figure 2.3: Annual Number of New Cases of Diagnosed Diabetes Among U.S. Adults Aged 18-79 Years, 1980-2011
 Figure 2.4: New Cases of Diabetes Diagnosed in the U.S. Adult Population by Age, 2010
 Figure 2.5: Prevalence of Diabetes by Age in the U.S., 2010
 Figure 2.6: Diagnosed Diabetes by Age in the U.S., 2013
 Figure 2.7: Number of Deaths from Diabetes by Age in the U.S., 2010
 Figure 2.8: Number of Diabetes Deaths by Race and Sex in the U.S., 2010
 Figure 2.9: Maintenance of Normal Blood Sugar Levels
 Figure 2.10: Prevalence of Self-Reported Obesity (BMI ≥30) Among U.S. Adults, 2012
 Figure 2.11: Prevalence of Obesity Among Adults in the U.S., 2009-2010
 Figure 2.12: Trends in Obesity Among Children and Adolescents in the U.S., 1988-2010
 Figure 2.13: Age-Adjusted Percentage of People with Diabetes Aged 35 Years or Older Reporting Heart Disease or Stroke, by Sex, in the U.S., 1997-2011
 Figure 2.14: Percentage of Adults with Diagnosed Diabetes Reporting Any Mobility Limitation, by Age, in the U.S., 1997-2011
 Figure 2.15: Number (in Millions) of Adults Aged 18 Years or Older with Diagnosed Diabetes Reporting Visual Impairment, in the U.S., 1997-2011
 Figure 2.16: Mean Diabetes Healthcare-Related Expenditures Per Adult (20-79 Years) with Diabetes (in U.S. Dollars), 2013
 Figure 2.17: How Diabetes Dollars are Spent in the U.S., 2012
 Figure 3.1: Worldwide HbA1c Testing Market, 2010-2019
 Figure 3.2: U.S. HbA1c Testing Market, 2010-2019
 Figure 3.3: Global HbA1c Self-Testing Market, 2010-2019
 Figure 4.1: Non-Enzymatic Glycation of Hemoglobin
 Figure 4.2: Boronate Affinity Binding of Glycated Protein
 Figure 4.3: Comparison of HbA1c and Blood Glucose Measurements Over a Four-Day-Period
 Figure 4.4: Range of Variation in HbA1c Assay
 Figure 4.5: Range of Variation in the FPG Assay
 Figure 7.1: CLIA Laboratories by Certificate Types

INDEX OF TABLES

- Table 2.1: Regional Estimates of the Number of Diabetes (20-79 Years) in Millions, 2013 and 2035
 Table 2.2: Countries with the Largest Numbers of Diabetics, 2013
 Table 2.3: Countries with the Largest Estimated Numbers of Diabetics, 2035
 Table 2.4: Worldwide Undiagnosed Diabetes in Adults (20-79 Years) by Region and Income Group, 2013
 Table 2.5: Countries with the Largest Number of Deaths Attributable to Diabetes, 2013
 Table 2.6: U.S. Population of Diagnosed Diabetics Aged 20-79 Years, 2013
 Table 2.7: Percentage of U.S. Adults with Diagnosed Diabetes by State, 2010
 Table 2.8: Ten Leading Diagnoses for Co-Morbid Chronic Diseases in the U.S.
 Table 2.9: Odds Ratio of Progression to Complications Associated with Type 2 Diabetes
 Table 2.10: Prevalence of Complications Among Patients with Diabetes
 Table 2.11: Novel Risk Factors and Possible Mechanisms of the Excess Risk of Coronary Heart Disease in Type 2 Diabetes Mellitus
 Table 2.12: Major Causes of End-Stage Renal Disease
 Table 2.13: Clinical Recommendations for Adults with Diabetes
 Table 2.14: Laboratory Assessment of Diabetic Vascular Disease
 Table 2.15: Average Years Gained Free of Diabetes-Related Disease with Intensive Management
 Table 2.16: Estimated Direct and Indirect Costs of Major Cardiovascular Diseases and Stroke in the U.S.,

2010

- Table 2.17: Cost of Diagnosed Diabetes in the U.S., 2012
- Table 2.18: Annual Cost of Care of United Healthcare Adult Members with Diabetes, 2009
- Table 2.19: Healthcare Utilization by Diabetic Patients, 2012
- Table 3.1: Worldwide HbA1c Testing Market, 2010-2019
- Table 3.2: U.S. HbA1c Testing Market, 2010-2019
- Table 3.3: Global HbA1c Self-Testing Market, 2010-2019
- Table 3.4: Key Players in the HbA1c Clinical Laboratory Market
- Table 3.5: Key Players in the HbA1c POC Market
- Table 3.6: Key Players in the HbA1c Self-Testing Market
- Table 3.7: Key Market Drivers for HbA1c Testing
- Table 4.1: Summary of the 2010 Consensus Statement on the Worldwide Standardization of HbA1c
- Table 4.2: Advantages of HbA1c versus Blood Glucose Testing
- Table 4.3: Disadvantages of HbA1c versus Blood Glucose Testing
- Table 4.4: HbA1c Testing Recommendations
- Table 4.5: Criteria for the Diagnosis of Diabetes
- Table 4.6: Categories of Increased Risk for Diabetes (Pre-Diabetes)
- Table 4.7: Glycemic Recommendations for Non-Pregnant Adults with Diabetes
- Table 4.8: Glycemic Recommendations for Women with Gestational Diabetes
- Table 4.9: Glycemic Recommendations for Pregnant Women with Pre-Existing Diabetes
- Table 4.10: Conditions Known to Interfere with HbA1c Assays
- Table 4.11: Interference from Hb Variants in Select HbA1c Testing Systems
- Table 4.12: History of NGSP Manufacturer Certification Criteria
- Table 4.13: Correlation of HbA1c with Mean Blood Glucose
- Table 5.1: HbA1c Testing Devices and Assays on the Market
- Table 5.2: Premier Hb9210 Placements Worldwide, 2012-2014
- Table 7.1: Financial Comparison for Moderate and Waived CLIA Labs

I would like to order:

Product name: Hemoglobin A1c Testing Markets
Product link: <http://marketpublishers.com/r/H80F53DC117EN.html>
Product ID: H80F53DC117EN
Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <http://marketpublishers.com/r/H80F53DC117EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at http://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**